SGLT2 Inhibitors May Open New Front In War Against Diabetes, Researchers Say

MedPage Today (5/18, Gever) reported that, according to research presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, “inhibitors of the type 2 sodium-glucose transporter (SGLT2) system…may open up an entirely new front in the war against diabetes, several researchers suggested.” As one researcher “explained, the excitement about SGLT2 inhibitors stems from their novel mechanism of action, which has nothing to do with hormonal secretion or responsiveness.” Instead, the drugs “cause excess blood glucose to be dumped into the urine.” A handful of SGLT2 inhibitors are now in clinical trials, including dapagliflozin, canagliflozin, and three others currently without generic names.

Courtesy of the Doctors at Shady Grove Eye and Vision Care; Optometrists, Ophthalmologists and Opticians serving the Rockville, Potomac and Gaithersburg Maryland suburbs of Washington DC.  For more information visit

Follow us on Twitter @EyeInfo


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: